Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
NK-1 receptor antagonist (anti-nausea)

Tradipitant

An investigational treatment for Gastroparesis.

FDA Complete Response Letter: Not Approvedby Vanda Pharmaceuticals
Preclinical
Phase 1
Phase 2
Phase 3
Approved
FDA Complete Response Letter: not approved, resubmission possible

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Tradipitant wherever you encounter it, plus the key facts at a glance.

Generic name
Tradipitant
Development code
VLY-686
Drug class
NK-1 receptor antagonist (anti-nausea)
Manufacturer
Vanda Pharmaceuticals
How it's taken
In Vanda's gastroparesis trials, adults took an 85mg tradipitant capsule by mouth twice a day.

Tradipitant is an anti-nausea capsule from Vanda Pharmaceuticals that the FDA has declined to approve for gastroparesis, a condition in which the stomach empties too slowly[1].

  • The FDA issued a complete response letter for tradipitant in gastroparesis on September 18, 2024 and then proposed refusing approval[1].
  • Tradipitant missed the main goal of its 12-week Phase 3 gastroparesis trial, where nausea scores fell 1.55 points on the drug and 1.49 points on placebo[2].
  • The FDA issued its decision on Vanda's hearing request on March 26, 2026 and posted it in public docket FDA-2024-N-5933[1].
  • Since December 30, 2025, tradipitant has been FDA-approved as Nereus for a different use: preventing vomiting caused by motion in adults[5][4].
Follow Tradipitant by email

We'll email you when the FDA acts on Tradipitant and when new trials for Gastroparesis open. Unsubscribe anytime.

You'll get, for Gastroparesis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

How Tradipitant works

Tradipitant blocks the neurokinin-1 (NK1) receptor, a docking site for a body chemical called substance P[4]. The Nereus label says tradipitant crosses into the brain and attaches to NK1 receptors there, though the exact way it works is not fully known[4]. A small Mayo Clinic study in 24 healthy volunteers found that tradipitant 85mg twice daily did not change how fast the stomach empties[11]. Vanda's gastroparesis trials measured relief of nausea rather than faster stomach emptying[2].

Clinical trial results

A first placebo-controlled trial (NCT02970968) gave 152 adults with diabetic or idiopathic gastroparesis (no known cause) 85mg tradipitant or placebo twice daily for 4 weeks[9]. Nausea scores in that trial fell 1.2 points on tradipitant versus 0.7 on placebo at week 4, a statistically significant difference[9]. The Phase 3 trial (NCT04028492) randomly assigned 201 adults to tradipitant or placebo for 12 weeks, plus 778 more in an open-label group[2].

Its main goal was the change in daily nausea severity at week 12, and it was not met: scores fell 1.55 points on tradipitant and 1.49 on placebo (p=0.74)[2]. Vanda's published follow-up analyses, done after the results were known, reported benefit in people with higher blood levels of tradipitant[10]. The FDA said the Phase 3 trial showed no significant benefit and that the earlier positive trial was not persuasive because of problems with how it was analyzed[12].

A 3-month open-label safety study (NCT06836557) enrolled 17 adults and was completed on March 30, 2026[3]. ClinicalTrials.gov showed no posted results for that safety study when checked on November 3, 2026[3].

Side effects and safety

Early trial safety observations

Tradipitant has no FDA-approved safety labeling for gastroparesis because it is not approved for that use[1]. In a January 2025 Federal Register notice, the FDA said the gastroparesis application lacked substantial evidence of effectiveness and had not shown the drug is safe, noting controlled safety data lasted only 12 weeks[12]. The Nereus label for motion-induced vomiting has no boxed warning and no contraindications[4].

The most common side effects on the Nereus label are sleepiness, headache and tiredness[4]. With a single 170mg dose, sleepiness occurred in 12% of people versus 6% on placebo[4]. Headache occurred in 10% versus 6% and tiredness in 8% versus 2% at that dose[4]. The Nereus label warns that tradipitant may impair driving or operating machinery, especially when combined with other sedating drugs or strong CYP3A4 inhibitors[4]. CYP3A4 inhibitors are medicines that slow the liver enzyme that breaks down tradipitant, which can raise its levels[4].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Tradipitant

In Vanda's gastroparesis trials, adults took an 85mg tradipitant capsule by mouth twice a day[9][10]. No dose is approved for gastroparesis because the FDA has not approved tradipitant for that use[1]. For the approved Nereus use, the label dose is a single dose of 85mg or 170mg (one or two 85mg capsules) taken about 60 minutes before travel on an empty stomach[4]. Nereus is approved for adults only, and the label allows no more than 1 dose in 24 hours[4].

Development history

Vanda submitted its gastroparesis application for tradipitant (NDA 218489) on September 18, 2023[1]. The FDA issued a complete response letter on September 18, 2024[1]. Vanda disputed the decision and said it would keep seeking approval and keep running its expanded access program for gastroparesis patients[6]. The FDA proposed refusing approval and offered a hearing in a Federal Register notice published January 16, 2025[1].

Vanda announced on January 27, 2025 that it had accepted the offer of a hearing[7]. Vanda and the FDA agreed in October 2025 to seek a pause of the gastroparesis proceedings before the FDA Commissioner until January 7, 2026[8]. The FDA issued its decision on Vanda's hearing request on March 26, 2026[1]. Separately, the FDA approved tradipitant as Nereus on December 30, 2025 to prevent vomiting caused by motion in adults[5][4].

Ask anything about Tradipitant
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Gastroparesis trials

Other Gastroparesis treatments

Common questions about Tradipitant

▸What is Tradipitant?

Tradipitant is an anti-nausea capsule from Vanda Pharmaceuticals that the FDA has declined to approve for gastroparesis, a condition in which the stomach empties too slowly[1]. The FDA issued a complete response letter for tradipitant in gastroparesis on September 18, 2024 and then proposed refusing approval[1]. Tradipitant missed the main goal of its 12-week Phase 3 gastroparesis trial, where nausea scores fell 1.55 points on the drug and 1.49 points on placebo[2]. The FDA issued its decision on Vanda's hearing request on March 26, 2026 and posted it in public docket FDA-2024-N-5933[1]. Since December 30, 2025, tradipitant has been FDA-approved as Nereus for a different use: preventing vomiting caused by motion in adults[5][4].

▸How does Tradipitant work?

Tradipitant blocks the neurokinin-1 (NK1) receptor, a docking site for a body chemical called substance P[4]. The Nereus label says tradipitant crosses into the brain and attaches to NK1 receptors there, though the exact way it works is not fully known[4]. A small Mayo Clinic study in 24 healthy volunteers found that tradipitant 85mg twice daily did not change how fast the stomach empties[11]. Vanda's gastroparesis trials measured relief of nausea rather than faster stomach emptying[2].

▸What are the side effects of Tradipitant?

Tradipitant has no FDA-approved safety labeling for gastroparesis because it is not approved for that use[1]. In a January 2025 Federal Register notice, the FDA said the gastroparesis application lacked substantial evidence of effectiveness and had not shown the drug is safe, noting controlled safety data lasted only 12 weeks[12]. The Nereus label for motion-induced vomiting has no boxed warning and no contraindications[4]. The most common side effects on the Nereus label are sleepiness, headache and tiredness[4]. With a single 170mg dose, sleepiness occurred in 12% of people versus 6% on placebo[4]. Headache occurred in 10% versus 6% and tiredness in 8% versus 2% at that dose[4]. The Nereus label warns that tradipitant may impair driving or operating machinery, especially when combined with other sedating drugs or strong CYP3A4 inhibitors[4]. CYP3A4 inhibitors are medicines that slow the liver enzyme that breaks down tradipitant, which can raise its levels[4].

▸How is Tradipitant taken?

In Vanda's gastroparesis trials, adults took an 85mg tradipitant capsule by mouth twice a day[9][10]. No dose is approved for gastroparesis because the FDA has not approved tradipitant for that use[1]. For the approved Nereus use, the label dose is a single dose of 85mg or 170mg (one or two 85mg capsules) taken about 60 minutes before travel on an empty stomach[4]. Nereus is approved for adults only, and the label allows no more than 1 dose in 24 hours[4].

▸Is Tradipitant FDA approved?

Tradipitant is currently in crl clinical trials for Gastroparesis. It has not yet received FDA approval.

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. U.S. Food and Drug Administration, Federal Register · 2026-03-31. Notice of Decision on a Hearing Request Regarding a Proposal To Refuse To Approve a New Drug Application for TRADIPITANT Capsules. https://www.federalregister.gov/documents/2026/03/31/2026-06187/notice-of-decision-on-a-hearing-request-regarding-a-proposal-to-refuse-to-approve-a-new-drug
  2. ClinicalTrials.gov · 2026-09-24. Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis (results posted September 24, 2026). https://clinicaltrials.gov/study/NCT04028492
  3. ClinicalTrials.gov · 2026-10-19. Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis. https://clinicaltrials.gov/study/NCT06836557
  4. U.S. National Library of Medicine, DailyMed · 2026-09. NEREUS (tradipitant) capsules, Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a021ebd-16ac-4354-b4b2-1c3950c091e5
  5. U.S. Food and Drug Administration, Drugs@FDA · 2025-12-30. NEREUS (tradipitant) NDA 220152, original approval December 30, 2025. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220152
  6. Vanda Pharmaceuticals · 2024-09-19. FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis. https://vandapharmaceuticalsinc.gcs-web.com/node/16141/pdf
  7. Vanda Pharmaceuticals · 2025-01-27. Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis. https://vandapharmaceuticalsinc.gcs-web.com/node/16231/pdf
  8. Vanda Pharmaceuticals (PR Newswire) · 2025-10-01. Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration. https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-collaborative-framework-for-resolution-of-disputes-with-the-us-food-and-drug-administration-302573077.html
  9. Gastroenterology (Carlin JL et al.) · 2021-01. Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial. https://doi.org/10.1053/j.gastro.2020.07.029
  10. Clinical Gastroenterology and Hepatology (Carlin JL et al.) · 2024-12. The Efficacy of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Phase 3 Randomized Placebo-Controlled Clinical Trial. https://doi.org/10.1016/j.cgh.2024.01.005
  11. Alimentary Pharmacology & Therapeutics (Khanna L et al.) · 2022-07. Clinical trial: a single-centre, randomised, controlled trial of tradipitant on satiation, gastric functions, and serum drug levels in healthy volunteers. https://doi.org/10.1111/apt.17065
  12. Federal Register (FDA) · 2025-01-16. Notice of opportunity for hearing on a proposal to refuse to approve a new drug application for tradipitant. https://www.federalregister.gov/documents/full_text/text/2025/01/16/2025-01027.txt

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Tradipitant by email

We'll email you when the FDA acts on Tradipitant and when new trials for Gastroparesis open. Unsubscribe anytime.

You'll get, for Gastroparesis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site